Brief: X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress
14/05/2025 21:16
May 14 (Reuters) - X4 Pharmaceuticals Inc XFOR.O: X4 PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION OF PHASE 2 CHRONIC NEUTROPENIA TRIAL DATA AT THE 30TH ANNUAL EHA CONGRESS Source text: ID:nGNX99FWpP Further company coverage: XFOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule